New Clinical Practice Guidelines: Strategies and Therapies to Manage the Obese Patient

San Diego, CA US
March 6, 2015

Friday, March 6, 2015 | 6:30 – 9:30 PM PST
Hilton San Diego Bayfront Hotel, Sapphire Ballroom D

This course is a live CME-certified ancillary symposium presented at ENDO 2015, the Endocrine Society's 97th Annual Meeting and Expo, held in San Deigo, California, March 5–8, 2015. ENDO 2015 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2015 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2015 to attend an ENDO 2015 ancillary symposium.

This activity is supported by an educational grant from Novo Nordisk Inc. 

SYMPOSIUM AGENDA

Welcome and Introduction
Program Director: Caroline M. Apovian, MD – Boston University School of Medicine

Gut-Brain Relationship in the Regulation of Weight and Appetite
Louis J. Aronne, MD – New York-Presbyterian Hospital/Weill Cornell Medical Center

Recommended Weight Loss and Clinical Benefits in Obese Patients
Daniel H. Bessesen, MD – Denver Health Medical Center/University of Colorado

Update on Clinical Practice Guidelines and Pharmacological Options
Donna H. Ryan, MD – Pennington Biomedical Research Center

Roundtable Discussion: Practical Application of New Clinical Practice Guidelines

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals treating overweight and obese individuals.

Learning Objectives

Upon completion of this educational activity, participants will be able to (or better able to):

  • Stratify risks and discuss the clinical recommendations and benefits of sustained weight loss in overweight and obese patients
  • Describe the role of hormonal and neural mechanisms in the regulation of appetite, food intake, and body weight
  • Discuss current strategies for reducing weight gain and promoting weight loss
  • Discuss the efficacy and safety of new and emerging treatment options in obesity management
  • Apply updated practice guidelines in a clinical setting

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Obesity
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
03/06/2015
Course expires: 
03/06/2016
Event starts: 
03/06/2015 - 6:30pm
Event ends: 
03/06/2015 - 9:30pm
Rating: 
4.5
Hilton San Diego Bayfront
1 Park Boulevard
Sapphire Ballroom B
San Diego, CA 92101
United States

Caroline M. Apovian, MD – Program Director
Professor of Medicine and Pediatrics
Boston University School of Medicine
Director, Nutrition & Weight Management Center
Section of Endocrinology, Diabetes, and Nutrition
Boston Medical Center
Boston, Massachusetts

Louis J. Aronne, MD
Sanford I. Weill Professor of Metabolic Research
Weill Cornell Medical College, Cornell University
Director, Comprehensive Weight Control Center
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Daniel H. Bessesen, MD
Chief of Endocrinology
Denver Health Medical Center
Professor of Medicine
University of Colorado
Denver, Colorado

Donna H. Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge, Louisiana

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Louis J. Aronne, MD: Advisory Board Member, Eisai, Ethicon Endo-surgery, Vivus USA, Zafgen; Advisory Board Member and Investigator, Novo Nordisk; Ownership Interest, Cardiometabolic Support Network, LLC; Ownership Interest and Stock Options, Myos Corporation; Investigator, Aspire Bariatrics, GI Dynamics
Caroline M. Apovian, MD: Advisory Board Member, Amylin Pharmaceuticals, Johnson&Johnson, MedaCorp, Novo Nordisk, NutriSystem, Orexigen, Vivus USA, Zafgen; Invesgitator, Aspire Bariatrics, , GI Dynamics, Oxigene
Daniel H. Bessesen, MD: DSMB Member, Enteromedics
Donna Ryan, MD: Consultant, Eisai, Janssen, Novo Nordisk, Scientific Intake, Takeda, Vivus

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Connie B. Newman, MD

The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl B. Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck;
Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E. Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron
Andrea L. Utz, MD, PhD: Investigator, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Larry Fox, MD; Michael S. Irwig, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation

Accreditation Period

Course opens: 
03/06/2015
Course expires: 
03/06/2016